Overview

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
Pfizer
Treatments:
Everolimus
Sirolimus
Sunitinib